Aurora Spine (TSXV:ASG) - Cotización, noticias y análisis

Resumen de acción ASG

Aurora Spine Corporation, a través de su filial Aurora Spine, Inc. se dedica al desarrollo y distribución de sistemas y dispositivos de fusión interespinosa mínimamente invasivos en Canadá.

Acerca de la empresa

ASG fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido un 29.7% al año en los últimos 5 años

Los accionistas han sido diluidos en el último año

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

No tiene una capitalización de mercado significativa (CA$23M)

+ 1 riesgos adicionales

Competidores de Aurora Spine Corporation

MedX Health

TSXV:MDX

CA$23.6m

Theralase Technologies

TSXV:TLT

CA$39.5m

Nanalysis Scientific

TSXV:NSCI

CA$50.9m

Scryb

CNSX:SCYB

CA$6.4m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Aurora Spine
Historical stock prices
Current Share Price	CA$0.28
52 Week High	CA$0.47
52 Week Low	CA$0.23
Beta	0.64
1 Month Change	-17.91%
3 Month Change	-19.12%
1 Year Change	-1.79%
3 Year Change	-64.29%
5 Year Change	-26.67%
Change since IPO	-79.63%

Noticias y actualizaciones recientes

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

Mar 19

Recent updates

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

Mar 19

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Oct 15

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aug 11

Rentabilidad de los accionistas

	ASG	CA Medical Equipment	Mercado CA
7D	-8.3%	2.3%	0.7%
1Y	-1.8%	-26.5%	4.9%

Rentabilidad vs. Industria: ASG superó al sector Canadian Medical Equipment , que obtuvo un rendimiento del -25.7% el año pasado.

Rentabilidad vs. Mercado: ASG obtuvo unos resultados inferiores a los del mercado Canadian, que fue del 5.5% el año pasado.

Volatilidad de los precios

Is ASG's price volatile compared to industry and market?
ASG volatility
ASG Average Weekly Movement	15.1%
Medical Equipment Industry Average Movement	11.4%
Market Average Movement	9.0%
10% most volatile stocks in CA Market	18.1%
10% least volatile stocks in CA Market	3.0%

Precio estable de las acciones: El precio de las acciones de ASG ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ASG(15%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Canadian.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2013	n/a	Trent Northcutt	www.aurora-spine.com

Aurora Spine Corporation, a través de su filial Aurora Spine, Inc., se dedica al desarrollo y la distribución de sistemas y dispositivos de fusión interespinosa mínimamente invasivos en Canadá. La empresa ofrece dispositivos de fusión lumbar interespinosa, como el ZIP, el ZIP ULTRA, el ZIP LP y el ZIP-51, para pacientes que padecen enfermedades degenerativas discales; y jaulas intercorporales de poliéter éter cetona recubiertas de Ti, que proporcionan espacio y estabilidad entre las vértebras mientras crece el hueso para completar el proceso de fusión. También suministra implantes de infusión vertebral recubiertos de plasma de titanio estéril para el crecimiento óseo, así como productos intercorporales como EOS, VOX, Echo, Echo SD y EchoXL para la sección lumbar de la columna vertebral, y Discovery para procedimientos cervicales.

Resumen de fundamentos de Aurora Spine Corporation

¿Cómo se comparan los beneficios e ingresos de Aurora Spine con su capitalización de mercado?
Estadísticas fundamentales de ASG
Capitalización bursátil	CA$21.14m
Beneficios(TTM)	-CA$3.05m
Ingresos (TTM)	CA$19.25m

1.1x

Ratio precio-ventas (PS)

-6.9x

Ratio precio-beneficio (PE)

¿Está ASG sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ASG
Ingresos	US$14.09m
Coste de los ingresos	US$6.34m
Beneficio bruto	US$7.74m
Otros gastos	US$9.98m
Beneficios	-US$2.23m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.029
Margen bruto	54.96%
Margen de beneficio neto	-15.86%
Ratio deuda/patrimonio	67.7%

¿Cómo se ha desempeñado ASG a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ASG

Recompensas

Análisis de riesgos

Competidores de Aurora Spine Corporation

TSXV:MDX

CA$23.6m

TSXV:TLT

CA$39.5m

TSXV:NSCI

CA$50.9m

CNSX:SCYB

CA$6.4m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Recent updates

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

First quarter 2021 earnings released: US$0.01 loss per share (vs US$0.011 loss in 1Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Receives Irb Approval to Commence Registration for Multicenter Study of Its Silo™ Device for Si Joint Pain

Full year 2020 earnings released

Aurora Spine Corporation Announces Launch of its SiLOTM Posterior SI Joint Fusion System

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

New 90-day high: CA$0.53

Aurora Spine Corporation(TSXV:ASG) dropped from S&P/TSX Venture Composite Index

New 90-day high: CA$0.44

New 90-day high: CA$0.38